Send us a text🧠 Clinical Context:Episodic migraines (<15 days/month) that don’t respond to traditional preventives.Patients often fail beta blockers, AEDs, TCAs, CCBs — need new options.🧪 Study – RCT on Atogepant:315 patients, mostly women, who failed ≥2 oral preventives.Randomized to atogepant 60 mg daily vs placebo.Follow-up: 3 months.📈 Outcomes:≥50% migraine reduction:51% in atogepant group vs 18% placebo.Most common side effect: Constipation (10% vs 3%).💊 Mechanism:CGRP receptor antagonist – blocks calcitonin gene-related peptide, a known migraine mediator.🧩 Clinical Application:Strong option for treatment-refractory episodic migraine.Easier than injectables; potential for earlier use in future guidelines.

Ver todos los episodios